FI964033A - Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja - Google Patents

Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja Download PDF

Info

Publication number
FI964033A
FI964033A FI964033A FI964033A FI964033A FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A FI 964033 A FI964033 A FI 964033A
Authority
FI
Finland
Prior art keywords
cells
treating
sertoli cells
disease
allografts
Prior art date
Application number
FI964033A
Other languages
English (en)
Swedish (sv)
Other versions
FI964033A0 (fi
FI120670B (fi
Inventor
Helena P Selawry
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Publication of FI964033A0 publication Critical patent/FI964033A0/fi
Publication of FI964033A publication Critical patent/FI964033A/fi
Application granted granted Critical
Publication of FI120670B publication Critical patent/FI120670B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI964033A 1994-04-13 1996-10-08 Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö FI120670B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
US21169594 1994-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts
US9504565 1995-04-13

Publications (3)

Publication Number Publication Date
FI964033A0 FI964033A0 (fi) 1996-10-08
FI964033A true FI964033A (fi) 1996-12-12
FI120670B FI120670B (fi) 2010-01-29

Family

ID=22787974

Family Applications (2)

Application Number Title Priority Date Filing Date
FI964033A FI120670B (fi) 1994-04-13 1996-10-08 Farmaseuttinen koostumus käsittäen Sertoli-soluja sekä niiden käyttö
FI20085733A FI120696B (fi) 1994-04-13 2008-07-18 Menetelmä solujen toipumisen ja jakautumisen lisäämiseksi

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20085733A FI120696B (fi) 1994-04-13 2008-07-18 Menetelmä solujen toipumisen ja jakautumisen lisäämiseksi

Country Status (12)

Country Link
US (3) US5725854A (fi)
EP (1) EP0755258B1 (fi)
JP (1) JPH09512015A (fi)
AT (1) ATE212230T1 (fi)
AU (1) AU715177B2 (fi)
CA (1) CA2187803C (fi)
DE (1) DE69525151T2 (fi)
DK (1) DK0755258T3 (fi)
ES (1) ES2169128T3 (fi)
FI (2) FI120670B (fi)
NO (1) NO320713B1 (fi)
WO (1) WO1995028167A1 (fi)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1125636C (zh) * 1995-02-08 2003-10-29 山之内欧洲有限公司 含有口服活性β－内酰胺的颗粒制备方法
US5830460A (en) 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
WO1996028174A1 (en) * 1995-03-13 1996-09-19 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
WO1996033264A1 (en) * 1995-04-20 1996-10-24 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
JP2002500202A (ja) * 1998-01-02 2002-01-08 タイタン ファーマシューティカルズ， インコーポレイテッド 免疫優位部位の生成のための色素性網膜上皮細胞の使用
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
JP5323293B2 (ja) * 1998-11-06 2013-10-23 セルトーリ テクノロジーズ エルエルシー 生物学的因子の生産および遺伝的に改変されたセルトーリ細胞を用いる免疫学的特権環境の創製
PT1435220E (pt) 1998-12-15 2006-12-29 Univ Mexico Nacional Autonoma Processo e dispositivo para facilitar a implantação de material biológico
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
EP1248640B1 (en) 2000-01-20 2006-10-04 Diabcell Pty Limited Preparation and xenotransplantation of porcine islets
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
CA2421036A1 (en) 2000-09-20 2002-03-28 Islet Sheet Medical Llc Fabrication of thin sheet bio-artificial organs
CN1289063C (zh) * 2001-05-11 2006-12-13 奥索-麦克尼尔药品公司 用于动物的免疫调节装置
US20050042746A1 (en) * 2001-09-28 2005-02-24 Olga Garkavenko Growing xenotransplant material in culture
RU2315621C2 (ru) * 2002-02-22 2008-01-27 Профи Мед Аб Применение ингибитора или антагониста тканевого фактора
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
EP1636346A4 (en) * 2003-06-24 2007-03-28 Diabcell Pty Ltd FROM PIG CULTIVATED PIG ISLE CELLS FOR XENOTRANSPLANTATION
AU2004266126B8 (en) * 2003-07-03 2011-07-28 Sertoli Technologies, Llc Compositions containing sertoli cells and myoid cells and use thereof in cellular transplants
US8263068B2 (en) * 2004-04-29 2012-09-11 Washington State University Research Foundation Modified cells expressing a protein that modulates activity of bHLH proteins, and uses thereof
MX2007001189A (es) 2004-07-29 2008-02-11 Univ Miami Dispositivos hibridos para terapias celulares.
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US20090028833A1 (en) * 2006-01-26 2009-01-29 John Constance M Proliferative Primary Human Sertoli Cell Cultures And Their Applications
JP2010500871A (ja) * 2006-07-28 2010-01-14 セルトセル・バイオテクノロジー・（ユーエス）・コーポレイション 成熟セルトリ細胞およびその使用
US9161901B2 (en) 2008-02-21 2015-10-20 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
KR101919728B1 (ko) 2009-08-28 2018-11-16 세르노바 코포레이션 세포 이식 방법 및 장치
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
US11565094B2 (en) 2017-10-17 2023-01-31 The Methodist Hospital System Delivery devices
US20220211770A1 (en) 2019-05-01 2022-07-07 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
US5725854A (en) 1998-03-10
ATE212230T1 (de) 2002-02-15
FI964033A0 (fi) 1996-10-08
DE69525151D1 (de) 2002-03-14
FI120670B (fi) 2010-01-29
DE69525151T2 (de) 2002-08-14
CA2187803C (en) 1999-09-28
AU2289395A (en) 1995-11-10
DK0755258T3 (da) 2002-05-13
EP0755258B1 (en) 2002-01-23
AU715177B2 (en) 2000-01-20
CA2187803A1 (en) 1995-10-26
EP0755258A1 (en) 1997-01-29
US5759534A (en) 1998-06-02
ES2169128T3 (es) 2002-07-01
FI120696B (fi) 2010-01-29
US5843430A (en) 1998-12-01
WO1995028167A1 (en) 1995-10-26
NO964342D0 (no) 1996-10-11
NO320713B1 (no) 2006-01-23
FI20085733A (fi) 2008-07-18
JPH09512015A (ja) 1997-12-02
NO964342L (no) 1996-12-13

Similar Documents

Publication Publication Date Title
FI964033A (fi) Menetelmiä sairauden hoitamiseksi käyttäen Sertoli-soluja ja allografteja tai ksengrafteja
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
HU9503141D0 (en) A method of enhancing cellular production molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
SE0000305D0 (sv) Förfarande och anordning vid superstruktur till implantat
IS4083A (is) Samsetning lyfjaefna, aðferð til framleiðslu hennar, og notkunar sem lyfja
DE69016667T2 (de) Stabilisierte komplexe bestehend aus stickoxyd/primäre amine zur verwendung als kardiovaskuläre wirkstoffe.
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
DK0698109T3 (da) Genoverføring til pancreasepithelceller
DK0643775T3 (da) Quinonderivater til forbedring af cellebioenergi
EA200100195A1 (ru) Ингибирование реакции "трансплантат против хозяина"
FI951511A (fi) IL-10:n käyttö insuliinista riippuvan diabetes mellituksen ennaltaestoon tai hoitoon
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
MX9302951A (es) Composicion farmaceutica para tratar la hiperproliferacion celular.
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
EA200000141A1 (ru) Способ лечения диабета тиазолидиндионом и сульфонилмочевиной
ATE210126T1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
DE59101818D1 (de) Arzneimittelzubereitung, enthaltend Stigmasta-4-en-3-on sowie deren Verwendung.
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
NO20012214L (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
AU7574700A (en) Methods and compositions for treatment of inflammatory disease using cadherin-11modulating agents
GEP19970991B (en) Method for Decay of Tumor Cells with Mammalia and Pharmacentical Composition for this Purpose
ATE253378T1 (de) Xenogene transplantation

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120670

Country of ref document: FI

MA Patent expired